Arcus Biosciences (RCUS)
(Real Time Quote from BATS)
$15.36 USD
-0.24 (-1.54%)
Updated Sep 25, 2024 02:31 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Arcus Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 117 | 112 | 383 | 78 | 15 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 117 | 112 | 383 | 78 | 15 |
Selling & Adminstrative & Depr. & Amort Expenses | 457 | 392 | 329 | 202 | 104 |
Income After Depreciation & Amortization | -340 | -280 | 54 | -124 | -89 |
Non-Operating Income | 39 | 14 | 0 | 1 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -301 | -266 | 55 | -123 | -85 |
Income Taxes | 6 | 1 | 2 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -307 | -267 | 53 | -123 | -85 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -307 | -267 | 53 | -123 | -85 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -351 | -274 | 63 | -120 | -88 |
Depreciation & Amortization (Cash Flow) | -11 | 6 | 9 | 4 | 1 |
Income After Depreciation & Amortization | -340 | -280 | 54 | -124 | -89 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 74.00 | 72.00 | 73.97 | 54.79 | 43.83 |
Diluted EPS Before Non-Recurring Items | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 |
Diluted Net EPS (GAAP) | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 |
Fiscal Year end for Arcus Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 39.00 | 145.00 | 31.00 | 32.00 | 29.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 39.00 | 145.00 | 31.00 | 32.00 | 29.00 |
SG&A, R&D, and Dept/Amort Expenses | 145.00 | 161.00 | 122.00 | 112.00 | 112.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -106.00 | -16.00 | -91.00 | -80.00 | -83.00 |
Non-Operating Income | 13.00 | 12.00 | 11.00 | 11.00 | 9.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -93.00 | -4.00 | -80.00 | -69.00 | -74.00 |
Income Taxes | 0.00 | 0.00 | 1.00 | 2.00 | 1.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -93.00 | -4.00 | -81.00 | -71.00 | -75.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -93.00 | -4.00 | -81.00 | -71.00 | -75.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 91.10 | 86.20 | 75.00 | 74.60 | 73.20 |
Diluted EPS Before Non-Recurring Items | -1.02 | -0.05 | -1.08 | -0.94 | -1.04 |
Diluted Net EPS (GAAP) | -1.02 | -0.05 | -1.08 | -0.94 | -1.04 |